WILMINGTON, Mass., July 29 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its second quarter corporate highlights and financial results press release will be issued on Tuesday, August 3rd at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Tuesday, August 3rd - 8:30 a.m. E.D.T. | |
If calling from North America use the following toll-free number: | |
800-647-4314 | |
International callers use: | |
502-719-4466 | |
Password - DUSA | |
A replay of the call will be available approximately 15 minutes following the call | |
North American callers: 877-863-0350 | |
International callers:858-244-1268 | |
The call will be accessible on our web site approximately six hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products. Levulan® Kerastick® for topical solution plus DUSA’s BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA is researching the use of Levulan® PDT for the treatment of AKs and the prevention of AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients. DUSA also markets other dermatology products, including ClindaReach®. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
SOURCE DUSA Pharmaceuticals, Inc.
